Editas Medicine Inc. (NASDAQ:EDIT)’s share price was up 2.4% during trading on Thursday . The company traded as high as $26.44 and last traded at $26.10, with a volume of 131,162 shares. The stock had previously closed at $25.48.

A number of equities analysts recently commented on EDIT shares. Cowen and Company reaffirmed a “buy” rating on shares of Editas Medicine in a research note on Monday, May 16th. Vetr raised Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price target on the stock in a research note on Monday, May 9th. Zacks Investment Research raised Editas Medicine from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, Jefferies Group reissued a “hold” rating and issued a $35.00 price target on shares of Editas Medicine in a research note on Friday, June 10th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $33.50.

The stock’s 50-day moving average is $27.95 and its 200 day moving average is $30.30. The firm’s market cap is $909.67 million.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.50. The firm earned $0.80 million during the quarter, compared to analysts’ expectations of $1.08 million. On average, equities research analysts anticipate that Editas Medicine Inc. will post ($2.35) EPS for the current year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.